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Abstract
Background: We investigated the treatments given, the outcome and the patient- and treatment-system dependent 
factors affecting treatment outcome in a national two-year cohort of culture-verified extra-pulmonary tuberculosis 
cases in Finland.
Methods: Medical records of all cases in 1995 - 1996 were abstracted to assess treatment and outcome, using the 
European recommendations for outcome monitoring. For risk factor analysis, outcome was divided into three groups: 
favourable, death and other unfavourable. Predictors of unfavourable outcome were assessed in univariate and 
multivariate analysis.
Results: In the study cohort of 276 cases, 116 (42.0%) were men and 160 (58.0%) women. The mean age was 65.7 years. 
A favourable outcome was achieved in 157/276 (56.9%) cases, consisting of those cured (8.0%) and treatment 
completed (48.9%). Death was the outcome in 17.4% (48/276) cases, including cases not treated. Other unfavourable 
outcomes took place in 45 (16.3%) cases. Significant independent risk factors for death in multinomial logistic 
regression model were male sex, high age, immunosuppression, any other than a pulmonary specialty being 
responsible at the end of the treatment and other than standard combination of treatment. For other unfavourable 
treatment outcomes, significant risk factor was treatment with INH + RIF + EMB/SM. Deep site of TB was inversely 
associated with the risk of other unfavourable outcome.
Conclusions: The proportion of favourable outcome was far below the goal set by the WHO. Age and comorbidities, 
playing an important role in treatment success, are not available in routine outcome data. Therefore, comparisons 
between countries should be made in cohort analyses incorporating data on comorbidities.
Background
World Health Organization (WHO) has set the interna-
tional target value for the favourable treatment outcome
to be 85% [1]. WHO and the International Union Against
Tuberculosis and Lung Disease (IUATLD) have published
joint recommendations for assessing the outcome of
tuberculosis treatment aiming at standardised reporting
in Europe [2-5]. These recommendations are mainly
designed for smear positive pulmonary tuberculosis
treated with standard short course protocol, but they are
commonly used for extra-pulmonary tuberculosis [6,7].
Many industrialized countries with comprehensive
health care and a secure supply of drugs free of charge for
patients have not reached the overall objective of 85%
with successful outcome, set by WHO [6-17]. In the rou-
tine data collection of the European Union and Western
European countries among previously untreated definite
pulmonary TB cases in 2005, 79% had a successful out-
come, 6% died, 4% failed or continued treatment beyond
12 months and 10% were lost to follow up. In our recent
cohort analysis of treatment outcome of culture-verified
pulmonary tuberculosis the proportion with favourable
outcome was only 65%, in contrast to the overall WHO
target of 85% [18].
There is limited information concerning countrywide
treatment outcome and risk factors for unfavourable
treatment outcome of extra-pulmonary tuberculosis in
low incidence countries. A problem in assessing treat-
ment outcome in extra-pulmonary tuberculosis is the
diversity in the nature of disease depending on the site of
disease. In Western Europe, successful outcome was
reported for 81% in extra-pulmonary tuberculosis [19].
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Most studies including extra-pulmonary cases have
reported results combined with pulmonary cases
[7,10,20]. In a Danish national cohort analysis, the pro-
portion with favourable outcome in extra-pulmonary
tuberculosis was 68% [6].
Our aim was to find out how extra-pulmonary tubercu-
losis is treated, as well as determine the treatment out-
come in Finland. We analyzed the risk factors, including
the patient and treatment system dependent factors, for
unfavorable treatment outcome of extra-pulmonary
tuberculosisin a national, population-based two-year
cohort of all culture-verified extra-pulmonary tuberculo-
sis cases to establish a basis for improving treatment out-
come results.
Methods
Study cohort, case definitions and data collection
The method of identifying all culture-confirmed tubercu-
losis cases in Finland, with the first positive culture sam-
ple date between January 1st, 1995, to December 31st,
1996 (N = 1059), present in either the National Infectious
Disease Register (NIDR) or acquired through a separate
query to all microbiological laboratories has been
described elsewhere [21].
A case of non-pulmonary tuberculosis was defined as
culture finding for M. tuberculosis in other specimen type
than respiratory secretion, in the absence of M. tubercu-
losis in culture from respiratory secretions and sputum
smear positivity for acid fast bacilli [18,22]. With this def-
inition, 322 (30% of the whole cohort) constituted the
base-frame for the extra-pulmonary tuberculosis cohort.
Out of the 322 cases in the extra-pulmonary tuberculo-
sis cohort, complete medical records were available for
311 (96.6%) (Figure 1). Among these 311 cases, four
(1.3%) had previously been treated for tuberculosis after
the year 1970, and were excluded from the outcome anal-
ysis as re-treatment cases. We further assessed the
detailed clinical information in patient charts in order to
divide the cases as deep and superficial disease. During
this assessment we identified sample types not directly
classifiable as pulmonary or non-pulmonary. All the
patient charts and autopsy reports of this group of cases
were assessed. We found 27 cases as having been errone-
ously classified by our original algorithm as extra-pulmo-
nary TB. These cases were diagnosed from the culture of
gastric aspirate or biopsy samples from lung tissue. In
four cases the information was not sufficient for judging
the location of the disease. These 31 cases were excluded
from the extra-pulmonary study group leaving 276 extra-
pulmonary cases with no previous treatment docu-
mented (Table 1). These extra-pulmonary TB cases were
divided to deep and superficial disease based on the site
of bacteriological sampling and/or ICD-codes. Lymph
node and skin tuberculosis were considered as superficial
and other forms as deep extra-pulmonary disease. If the
same patient had both deep and superficial disease, the
case was classified as deep disease.
Definitions of treatment
Tuberculosis treatment was initiated in and supervised by
the pulmonary departments of public hospitals in the
great majority of cases. Chemotherapy combination was
decided by the treating physician. In our retrospective
record review, the combination actually given to each
patient was grouped into six categories (Table 2) in order
to describe the variability in treatment combinations
used. Definitions for the grouping were based on the
national recommendations in Finland following the rec-
ommendations by WHO, ATS and BTS [23-28]. We have
previously described the treatment grouping in detail
Table 1: The composition of extra-pulmonary study cohort
Form of tuberculosis N Percent
Lymp node 106 38.4
Skin 13 4.7
Pleural 50 18.1
Uninary and reproductive system 60 21.7
Bone and joints 20 7.3
Other 27 9.8
Total 276 100.0
Figure 1 Composition of the national study cohort of culture-
confirmed extra-pulmonary tuberculosis cases.
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[18]. Pauses of chemotherapy were recorded only when
lasting at least one week, and calculated only for standard
treatments.
Definitions of outcome
The categories of WHO/EuroTB recommendation for
outcome monitoring are cure, treatment completed, fail-
ure, death, treatment interrupted (default), transfer out,
and on treatment at 12 months [5]. The duration of the
follow up period is defined as 12 months from the begin-
ning of the treatment or the date of diagnosis, and the
first outcome registered as final.
The WHO/EuroTB category 'treatment interrupted'
includes all interruptions, whether caused by a patient or
by a treating physician. For analysing these two sepa-
rately, we divided 'treatment interrupted' into 'physician's
decision to stop early' and 'default' for interruptions due
to patient only [18]. The outcome was recorded as 'death',
if the case died before starting the treatment, during the
treatment, or the date of death was within 14 days after
cessation of the anti-TB drugs.
The outcome categories used are listed in Table 3. The
outcome was categorized as favourable in cases of cure
and treatment completed, and as unfavourable in cases of
failure, death, default, physician's decision to stop early
and transfer out.
Definitions of origin, social and medical risk factors
A case was defined as immigrant if the country of birth
was not Finland or, in the absence of country of birth, the
nationality was other than Finnish. Immunosuppressive
treatment was defined as corticosteroid treatment (>40
mg per day of any duration, or any daily dose with treat-
ment duration exceeding one month), cytotoxic or
cyclosporine treatment, or radiation therapy during the
preceding year. For inclusion in the group of social risk
factors, a case had a history of alcohol abuse, unemploy-
ment, imprisonment or homelessness recorded in patient
records. To be included in the diabetes risk group the
case had juvenile or adult onset disease on medication.
Definitions of characteristics of treatment system
Specialty responsible for treatment was that of the unit
treating patient as an inpatient or outpatient.
Ethical review
The ethics approval for this study was acquired from the
National Research and Development Centre for Welfare
and Health.
Statistical methods
Median age comparisons where tested using Median test.
For comparison of proportions, Chi-square or Fisher's
Table 2: Definitions used in describing the treatment given to the cases in a national cohort of patients with extra-
pulmonary tuberculosis
Treatment group Drugs used in intensive phase Duration of intensive 
phase [days]
Drugs used in 
continuation phase
Total duration of 
treatment [months]
Standard treatment A isoniazid + rifampicin + pyrazinamide At least 54 isoniazid + rifampicin At least 5 1/2
Standard treatment B isoniazid + rifampicin + ethambutol or 
streptomycin
At least 54 isoniazid + rifampicin At least 8
Standard treatment 
with short intensive 
phase C
isoniazid + rifampicin + pyrazinamide 
or ethambutol or streptomycin
Less than 54 isoniazid + rifampicin At least 5 1/2 for A At least 
8 for B
Standard treatment D >4 tuberculosis drugs, including the 
drugs in Standard treatment A or B
At least 54 isoniazid + rifampicin 
+ any other anti-
tuberculosis drug(s)
At least 5 1/2 for A At least 
8 for B
Other combination of 
tuberculosis drugs
Non-standard combinations of 
tuberculosis drugs, excluding the 
combinations above
NA2 Any combination of 
antituberculosis drugs
NA
Ineffective treatment One antituberculosis drug used alone 
or in combination with a drug with 
limited antituberculosis activity 1
NA NA NA
1E.g. fluoroquinolones
2NA = not applicableVasankari et al. BMC Public Health 2010, 10:399
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generalised exact test with Monte Carlo simulation was
used. Stata 11.0 (StataCorp LP Texas, USA) and IBM
SPSS for Windows, version 18.0.2 (Chicago, IL, USA) was
used for statistical calculations. We used binary and mul-
tinomial logistic regression model to assess the relation-
ships between all predictors that were found to be
significant in pulmonary tuberculosis (to compare extra-
pulmonary tuberculosis to pulmonary tuberculosis in
respect to these variables), and other variables which in
the univariate analysis had a p-value less than 0.20, with
binomial and trinomial outcome variables, in which the
reference class was favourable outcome. To the final
model, predictors were selected by forcing all those vari-
ables that were significant in pulmonary tuberculosis, and
from other variables selection was by forward stepwise
method. P-values under 5% were considered as signifi-
cant. For univariate results also Chi squared test and
Fisher's exact test were used.
Results
In the study cohort of 276 cases, 116 (42.0%) were men
and 160 (58.0%) women. The median age was 70.1 years.
There were 170 cases aged >65 years (61.6%). The pro-
portion of immigrants was 10.9% (30 cases), mainly from
developing countries. There were no cases of HIV-coin-
fection in the cohort. There was one prisoner in the study
cohort.
Treatment given
Tuberculosis chemotherapy was given to 257 (93.1%) of
the 276 cases. Half of the cases (140/257; 54.5%) received
standard treatment A, 28 (10.9%) received standard treat-
ment B, and 30 (11.7%) received standard treatment with
additional drugs (D) (Table 4). In 18 (7.0%) of the cases
the intensive phase was short (category C). A total of 41
cases (16.0%) received either other combinations of
tuberculosis drugs or ineffective treatment. Most of the
cases (177/257, 68.9%), were treated with the same com-
bination during the whole treatment. Nineteen (6.9%) of
the 276 cases were untreated, the majority (16; 84.2%) of
whom died before the diagnosis of tuberculosis was
established.
The median age differed significantly between the
treatment groups; it was 70,5 (range 6,9-94,4) years for
category A, 72.6 (18,5-90,4) for category B, 58.2 (6,6-91,0)
for category C, 57.5 (15,1-88,2) for category D, 72.6 (60,8-
71,6) for other combinations and 67.8 (18,6-94,4) for inef-
fective treatment (p = 0.005). There were 62 (44.3%) men
in treatment group A, 10 (35.7%) in B, 6 (33.3%) in C, 15
(50.0%) in D, 8 (22.2%) in other combinations and 4
(80.0%) in ineffective treatment group. The difference
was significant (p = 0.04). There was no statistical differ-
ence between groups regarding the presence of a social
risk factor (p = 0.32).
Outcome of treatment
A favourable outcome was achieved in 157/276 (56.9%) of
the cases, consisting of those cured (8.0%) and treatment
completed (48.9%). The proportion with favourable out-
come varied between 35.7 to 80.0% in different treatment
groups. There were no treatment failures in the cohort.
Table 3: Summary of the outcome criteria used in the study
Indicator Definition
Cure Treatment completion and:
- culture becoming negative on samples 
taken at the end of treatment and on at least 
one previous occasion or
- sputum microscopy becoming negative for 
AFB at the end of treatment and on at least 
one previous occasion.
Treatment 
completed
Treatment completion, not meeting the 
criteria to be classified as Cured or Failed
Death Death before starting treatment or during 
treatment, irrespective of cause.
Transfer out Patient referred to another clinical unit for 
treatment and final outcome unknown
Failed Culture or sputum microscopy remaining 
positive or becoming positive again at 5 
months or later during treatment.
Default Treatment interrupted for 2 consecutive 
months, or more for reasons due to patient.
Physician's 
decision 
to stop early
Treatment interrupted for 2 consecutive 
months, or more due to physician's decision.
On 
treatment at 
12 months
Patient still on treatment at 12 months who 
did not meet any other outcome during 
treatment. This includes patients with:
- initial treatment changed due to 
polyresistance (ie. resistance to at least two 
first line drugs) on the isolate taken at the start 
of treatment.
- treatment prolonged because of side 
effects/complications
- initial regimen planned for >12 months
- information on the reasons for being still on 
treatment not available
Not known Information on outcome not available, for 
cases not known to have been transferredV
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Table 4: Treatment outcome in the study cohort of 276 extra-pulmonary tuberculosis cases according to the WHO/EuroTB classification, modified for 'default' and 
'physician's decision to stop early'
Treatment group FAVOURABLE UNFAVOURABLE1 On 
treatment at 
12 months
Not known Total
Cured Treatment 
completed
Subtotal Death Transfer out Default Physician's decision 
to stop early
Subtotal
Standard treatment A 15
10.7%
82
58.6%
97
69.3%
18
12.9%
0
0
3
2.1%
14
10.0%
35
25.0%
7
5.0%
1
0.7%
140
100%
Standard treatment B 1
3.6%
9
32.1%
10
35.7%
5
17.9%
01
3.6%
8
28.6%
14
50.0%
4
14.3%
02 8
100%
Standard treatment with short intensive 
phase C
01 4
77.8%
14
77.8%
1
5.6%
00 2
11.1%
3
16.7%
1
5.6%
01 8
100%
Standard treatment D 3
10.0%
10
33.3%
13
43.3%
1
3.3%
01
3.3%
4
13.3%
6
20.0%
11
36.7%
03 0
100%
Other combination of tuberculosis drugs 3
8.3%
16
44.4%
19
52.7%
6
16.7%
1
2.8%
5
13.9%
3
8.3%
15
41.7%
1
2.8%
1
2.8%
36
100%
Ineffective treatment 0 4
80.0%
4
80.0%
1
20.0%
00 0 1
20.0%
00 5
100%
Overall outcome with any treatment 22 135
52.5%
157
61.1%
32
12.5%
1
0.4%
10
3.9%
31
12.1%
74
28.8%
24
9.3%
2
0.8%
257
100%
No treatment NA NA NA 16
84.2%
03 2
15.8%
01 9
100%
00 1 9
100%
Total 22
8.0%
135
48.9%
157
56.9%
48
17.4%
1
0.4%
13
4.7%
31
11.2%
93
33.7%
24
8.7%
2
0.7%
276
100%
1There were no failures in the cohort.
2The treating physician decided not to give any treatment.Vasankari et al. BMC Public Health 2010, 10:399
http://www.biomedcentral.com/1471-2458/10/399
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The proportion of cases defaulting or transferring out
was 14/276 (5.1%), and of them 5/14 (35.7%) were immi-
grants and 2/14 (14.3%) had a social risk factor. In 31
(11.2%) cases treatment was stopped prematurely by phy-
sician. Death was the outcome in 17.4% (48/276) cases,
including cases not treated.
The proportion of cases with favourable outcome dif-
fered significantly between treatment groups (P < 0.001),
and was smallest in treatment groups B and D (35.7% and
43.3%). The proportion of deaths differed between
groups, and was lowest in treatment group D (3.3%). In
the ineffective treatment group the proportion of deaths
was higher (20.0% versus 12.1%) than in the other combi-
nations of TB drugs.
24 of the cases were still on treatment at 12 months,
and in two cases it was not possible to judge the outcome
from the information available. Of the remaining 250
cases, 19 were not treated, among them 11 (57.9%) were
men and 8 (42.1%) women. Of this group, with a median
age of 81.0 years, 16 died before treatment and 3 were left
untreated. These 45 cases were excluded from the analy-
sis of risk factors of poor treatment outcome.
Analysis of risk factors for unfavourable outcome
In univariate analysis, patient-related risk factors which
were significantly associated (p < 0.05) with death, were
high age, immunosuppression and diabetes (Table 5).
Treatment system -related risk factors which were signifi-
cantly associated with death were the specialty of the
treating unit (internal medicine, general medicine in pri-
mary care), change of specialty responsible for treatment
and less than five treated cases per year per unit (Table 6).
There was no statistically significant patient-related per-
sonal risk factor association for other unfavourable out-
come (i.e. transfer out, default or physician's decision to
stop early) (Table 5). Treatment system -related signifi-
cant risk factors for other unfavourable outcome were
standard treatment B, other treatment combination,
change in treatment group and pause(s) during treatment
(Table 6). For all unfavourable outcomes together, i.e.
death and other unfavourable outcome combined, signifi-
cant predictors in univariate analysis were high age,
immunosuppression, specialty of the treating unit (gen-
eral medicine in primary care), change of specialty
responsible for treatment, less than five treated cases per
year per unit, standard treatment B, other treatment
combination and pause(s) during treatment.
Significant independent risk factors for death in multi-
nomial logistic regression model were male sex, high age,
immunosuppression, any other than a pulmonary spe-
cialty being responsible at the end of the treatment and
other than standard combination of treatment. For other
unfavourable treatment outcomes, significant risk factor
was treatment group B (Table 7). Deep site of TB was
inversely associated with the risk of other unfavourable
outcome (p = 0.02).
For death and other unfavourable outcomes together,
significant risk factors in the binary logistic regression
model were high age (p = 0.02), immunosuppression (p =
0.001), treatment group B (p < 0.001) and any other than
a pulmonary, internal and general medicine specialty
being responsible at the end of the treatment (p = 0.01).
Almost significant risk factors were male sex (p = 0.06)
and specialty of the treating unit (general medicine in pri-
mary care) (p = 0.06). Deep site of tuberculosis was
almost significantly protective (p = 0.07) (Table 7).
When we analysed all 250 cases in the cohort with
known outcome, including those 19 without treatment,
the associations observed in multivariate analysis as sig-
nificant were the same as with the 231 cases of the pre-
sented analysis.
Discussion
In a two-year national cohort of culture-confirmed extra-
pulmonary tuberculosis cases, we observed a favourable
outcome of treatment in 57%, far less than the target level
presented by WHO for favourable outcomes. High death
rate, physician's decision to stop the treatment too early
and treatment still going on at 12 months were the main
reasons.
The proportion of favourable outcome in our extra-pul-
monary tuberculosis cohort was even smaller than for
culture- proven pulmonary tuberculosis during the same
time period [18]. Our proportion with favourable out-
come was smaller than that in a Danish national cohort
analysis, where the proportion of favourable outcome in
extra-pulmonary tuberculosis was 68% [6], or the 81%
reported for extra-pulmonary tuberculosis in the routine
surveillance data collection of the European Union and
other Western European countries [19]. In a number of
studies combining outcome in pulmonary and extra-pul-
monary cases, the proportions with favorable treatment
outcomes have ranged between 68 - 82% [7,10,20], and
are not comparable to our current figures. The large pro-
portion of lymph node and skin manifestations in extra-
pulmonary tuberculosis, for the outcome of which the
impact from systemic chemotherapy may be different
from pulmonary and deep extra-pulmonary tuberculosis,
warrants separate assessment of the outcome of extra-
pulmonary tuberculosis.
The outcome analysis recommended by WHO and the
International Union Against Tuberculosis and Lung Dis-
ease (IUATLD) is mainly developed for smear or culture
positive pulmonary disease. It can be used in extra-pul-
monary disease, but due to the great diversity in the clini-
cal presentation of extra-pulmonary disease and
treatment regimens used, it might need development for
this purpose. For example, in TB meningitis, the pro-V
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Table 5: Univariate analysis of the association of patient -related characteristics with an unfavourable outcome in 231 cases treated for at least 24 hours
Variable Total Death Other unfavourable All unfavourable (death and other) together
N N OR (95% CI) p N OR (95% CI) p N OR (95% CI) p
Sex female 137 15 1 26 1 41 1
male 94 17 1.78 (0.83-3.82) 0.14 16 0.97 (0.48-1.95) 0.93 33 1.27 (0.72-2.21) 0.41
Age at diagnosis risk per five years 1.53 (1.24-1.88) <0.001 1.07 (0.95-1.21) 0.29 1.18 (1.03-1.34) 0.01
TB history no 200 30 1 35 1 65 1
yes 31 2 0.41 (0.09-1.83) 0.24 7 1.23 (0.49-3.11) 0.67 9 0.85 (0.37-1.95) 0.70
Social risk factor no 215 31 1 40 1 71 1
yes 16 1 0.36 (0.05-2.83) 0.33 2 0.55 (0.12-2.56) 0.45 3 0.47 (0.13-1.67) 0.25
Site of tuberculosis superficial 114 13 1 26 1 39 1
deep 117 19 1.34 (0.62- 2.89) 0.46 16 0.56 (0.28-1.13) 0.11 35 0.82 (0.47-1.43) 0.48
Immunosuppression no 204 22 1 38 1 60 1
yes 27 10 5.03 (2.00-12.87) 0.001 4 1.17 (0.36-3.78) 0.80 14 2.58 (1.15-5.83) 0.02
Malignancy1 no 223 29 1 42 1 71 1
yes 7 2 2.02 (0.38-10.9) 0.41 0 0 1.00 2 0.84 (0.16-4.46) 0.84
Diabetes no 205 25 1 37 1 62 1
yes 26 7 2.86 (1.05-7.79) 0.04 5 1.38 (0.47-4.08) 0.56 12 1.98 (0.86-4.52) 0.11
Total 231 32 42 74
1 Information is missing for one case.
2 Max likelihood estimate is not finite.
Significant p-values are darkened.V
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Table 6: Univariate analysis of the association of treatment system -related characteristics with an unfavourable outcome in 231 cases treated for at least 24 hours
Variable Total Death Other unfavourable All unfavourable (death and other) together
N N OR (95% CI) p N OR (95% CI) p N OR (95% CI) p
Specialty responsible for starting treatment pulmonary 185 18 1 34 1 52 1
internal medicine 33 9 3.50 (1.38-8.90) 0.009 5 1.02 (0.36-2.96) 0.96 14 0.43 (0.06-2.97) 0.39
general medicine 2 2 Inf3 1.00 0 1.05 1.00 2 0.23 (0.04-1.20) 0.08
other 11 3 4.43 (0.98-20.14) 0.05 3 2.35 (0.53-10.31) 0.26 6 0.61 (0.12-2.10) 0.37
Specialty responsible for ending treatment pulmonary 161 8 1 34 1 42 1
internal medicine 29 7 6.13 (1.97-19.05) 0.002 5 1.03 (0.35-2.99) 0.96 12 2.00 (0.88-4.53) 0.10
general medicine 35 16 14.00 (5.21-37.65) <0.001 2 0.41 (0.09-1.87) 0.25 18 3.00 (1.42-6.35) 0.004
other 6 1 3.72 (0.37-37.29) 0.26 1 0.41 (0.09-8.09) 0.91 2 1.42 (0.25-8.02) 0.69
Change of specialty responsible for 
treatment
no 174 16 1 32 1 48 1
yes 57 16 4.06 (1.83-9.02) 0.001 10 1.27 (0.56-2.86) 0.58 26 2.20 (1.19-4.09) 0.01
Number of cases per year for unit responsible 
for ending treatment
1 - 4 55 16 4.37 (1.86-10.28) 0.001 10 1.49 (0.63-3.50) 0.36 26 2.51 (1.30-4.84) 0.006
5 - 10 12 1 0.88 (0.10-7.56) 0.91 2 0.96 (0.19-4.76) 0.96 3 0.93 (0.24-3.64) 0.92
11 - 29 34 3 1.03 (0.27-3.96) 0.96 8 1.50 (0.59-3.80) 0.39 11 1.34 (0.59-3.03) 0.49
30 - 129 12 1 22 1 34 1V
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Treatment group standard 
treatment A
132 18 1 17 1 35 1
standard 
treatment B
24 5 2.69 (0.82-8.82) 0.10 9 5.14 (1.82-14.49) 0.002 14 3.88 (1.58-9.53) 0.003
standard 
treatment C
17 1 0.40 (0.05-3.11) 0.37 2 0.82 (0.17-3.91) 0.80 3 0.59 (0.16-2.19) 0.43
standard 
treatment D
19 1 0.41 (0.05-3.37) 0.41 5 2.19 (0.69-6.95) 0.18 6 1.28 (0.45-3.62) 0.64
other 
combination
34 6 1.70 (0.60-4.84) 0.32 9 2.70 (1.05-6.96) 0.04 15 2.19 (1.00-4.77) 0.049
ineffective 5 1 1.35 (0.14-12.76) 0.80 0 0 1.00 1 0.69 (0.07-6.41) 0.74
Change in treatment group no 159 22 1 22 1 44 1
yes 72 10 1.00 (0.43-2.34) 0.99 20 2.12 (1.05-4.27) 0.04 30 1.56 (0.87-2.80) 0.13
Pause of treatment no 169 25 1 22 1 47 1
yes 62 7 0.98 (0.39-2.45) 0.96 20 3.17 (1.55-6.46) 0.002 27 2.00 (1.09-3.66) 0.02
Pause during intensive phase1 no 183 25 1 24 1 49 1
yes 47 6 1.40 (0.52-3.78) 0.51 18 4.37 (2.05-9.29) <0.001 24 2.88 (1.43-5.78) 0.003
Pause during intensive phase, due to side 
effect
no 191 26 1 27 1 53 1
yes 40 6 1.68 (0.61-4.60) 0.32 15 4.04 (1.82-8.92) 0.001 21 2.85 (1.48-5.51) 0.002
Pause during continuation phase no 171 12 1 25 1 37 1
Table 6: Univariate analysis of the association of treatment system -related characteristics with an unfavourable outcome in 231 cases treated for at least 24 hours V
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yes 34 2 1.12 (0.23-5.36) 0.89 12 3.22 (1.40-7.40) 0.006 14 2.53 (1.17-5.50) 0.02
NA (other + 
ineffective)
26 18 5 23
Total 231 32 42 74
Significant p-values are darkened.
1 Information missing for one case
2 Information missing for 3 cases
3 Max likelihood estimate is not finite.
Table 6: Univariate analysis of the association of treatment system -related characteristics with an unfavourable outcome in 231 cases treated for at least 24 hours V
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Table 7: Multivariate analysis of 231 cases treated at least 24 hours, odds ratio for death or other unfavourable (transfer out, default, physician's decision to stop 
early) outcomes. 
Variable Death Other unfavourable All unfavourable (death and other) together
N OR (95% CI) p N OR (95% CI) p N OR (95% CI) p
Sex female 15 1 26 1 41 1
male 17 8.53 (3.23-22.50) <0.001 16 1.24 (0.55-2.84) 0.61 33 2.04 (0.98-4.24) 0.06
Age at diagnosis risk per five years 1.10 (1.06-1.14) <0.001 1.01 (0.98-1.04) 0.30 1.16 (1.03-1.31) 0.02
Immunosuppression no 22 1 38 1 60 1
yes 10 5.58 (1.92-16.21) 0.002 4 1.22 (0.38-3.90) 0.74 14 2.07 (1.33-3.22) 0.001
TB history no 30 1 35 1 75 1
yes 2 0.27 (0.05-1.59) 0.15 7 1.04 (0.44-2.43) 0.93 9 0.74 (0.32-1.70) 0.48
Site of tuberculosis superficial 13 1 26 1 39 1
deep 19 1.48 (0.68-3.20) 0.32 16 0.46 (0.24-0.86) 0.02 35 0.62 (0.38-1.03) 0.07
Specialty responsible for ending treatment pulmonary 8 1 34 1 42 1
internal medicine 7 6.85 (2.24-20.97) 0.001 5 1.09 (0.32-3.72) 0.90 12 1.89 (0.86-4.14) 0.11
general medicine 16 28.91 (5.95-140.51) <0.001 2 0.33 (0.08-1.38) 0.13 18 2.59 (0.97-6.91) 0.06
other 1 173.65 (12.97-2325.22) <0.001 1 1.99 (0.79-5.01) 0.14 2 5.27 (1.48-18.73) 0.01
Pause of treatment no 25 1 22 1 47 1
yes 7 0.25 (0.58-1.07) 0.06 20 2.48 (0.92-6.69) 0.07 27 1.28 (0.54-3.07) 0.58V
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Treatment group standard treatment A 18 1 17 1 35 1
standard treatment B 5 3.88 (0.89-16.87) 0.07 9 3.67 (1.52-8.85) 0.004 14 4.32 (2.00-9.31) <0.001
standard treatment C 1 1.49 (0.27-8.12) 0.65 2 0.75 (0.14-4.00) 0.73 3 0.98 (0.22-4.27) 0.98
standard treatment D 1 1.26 (0.10-16.51) 0.86 5 2.52 (0.50-12.80) 0.27 6 2.46 (0.76-8.00) 0.13
other combination 6 5.06 (1.13-22.57) 0.03 9 1.47 (0.35-6.24) 0.60 15 2.02 (0.56-7.31) 0.28
ineffective 1 3.44 (0.54-22.00) 0.19 0 0 <0.001 1 0.59 (0.11-3.20) 0.54
Significant p-values are darkened.
Reference category is favourable treatment outcome.
Table 7: Multivariate analysis of 231 cases treated at least 24 hours, odds ratio for death or other unfavourable (transfer out, default, physician's decision to stop 
early) outcomes.  (Continued)Vasankari et al. BMC Public Health 2010, 10:399
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posed treatment duration is 12 months, and the case may
therefore be categorized in the still on treatment cate-
gory. There is also difficulty in acquiring culture samples
late in the treatment for defining category cure. On the
other hand, the proportion of tuberculosis of different
extra-pulmonary organ locations is small in developed
countries, and it would be impractical to have many dif-
ferent outcome assessment systems for pulmonary and
extra-pulmonary disease.
The proportion of those being still on treatment at 12
months was 8.7%, higher than the 3.9% in the pulmonary
cohort [18]. The wide clinical diversity of extra-pulmo-
nary TB can explain this partly, because the treatment
time in the tuberculosis of central nervous system and
bones is usually longer. It is also possible that the treat-
ment of the wide variety of different forms of extra-pul-
monary tuberculosis is even more unfamiliar to doctors
than treating pulmonary tuberculosis.
There are no earlier studies of risk factors for unfavor-
able outcome in extra-pulmonary TB. Compared to those
studies including all forms of disease, male sex, high age
and immunosuppression were risk factors for death as
has been previously reported [6,8,29]. Any other than a
pulmonary specialty being responsible at the end of the
treatment as a risk factor for death was noticed already in
our pulmonary cohort [22], but other than standard com-
bination of treatment as a risk factor was noticed only in
this study. Even though our data allowed controlling for a
range of comorbid states, it is possible that, in a patient
population where half of the cases are older than 65 years,
there could be more comorbidity in the subgroup that
ends up being treated in internal medicine and geriatric
services. In the univariate analysis there was a reverse
association of death with the number of cases treated per
year by the unit in charge of ending the treatment. How-
ever, this association did not remain an independent pre-
dictor in multivariable analysis, in contrast to our earlier
study on pulmonary tuberculosis [22].
The finding that deep localization of TB was inversely
associated with the risk of other unfavourable outcomes
than death was new. It is probable that the efforts to
ensure secure the continuity of treatment depend on the
severity of TB disease. Superficial disease may be consid-
ered more benign. Our previous finding in pulmonary
tuberculosis of the protective effect of history of earlier
tuberculosis was not observed in this study population.
The site of disease was not significantly associated with
the risk of death. It seems that other factors like age and
other comorbidities are more important risk factors of
death, and the site of disease (deep or superficial) plays a
smaller role.
In our previous analysis on pulmonary tuberculosis in
the same two-year cohort of culture-verified tuberculosis,
a case was defined as pulmonary using the case definition
of NIDR, i.e. as a culture finding for M. tuberculosis in
sputum or bronchoalveolar lavage (BAL), or as a culture
finding for M. tuberculosis from another sample type in a
case with sputum smear positive for acid fast bacilli. Now
the analysis of the remaining part of the two-year cohort,
revealed a group of 27 pulmonary cases with biopsy sam-
ples or gastric aspirate samples. This same bias existed
probably in the statistics of NIDR, but it can be consid-
ered small compared to the total figures. The NIDR sys-
tem is highly computerized, and a thorough evaluation of
all TB cases is not possible with the resources available.
However all cases in those less than 16 years of age are
investigated in detail.
Due to the strictly controlled data collection process
and high coverage, as reported previously [21], the data is
highly representative. Only in 13 cases we could not trace
enough patient record data to classify them. TB treat-
ment recommendations and treatment organisation, the
age distribution and the case fatality rate have all
remained unchanged since the study period in 1995-
1996, making the analysis and conclusions valid for the
present.
Conclusions
The proportion of favourable outcome was far below the
goal set by the WHO. Age and comorbidities, which play
an important role in treatment success, are not usually
analyzed for the routine outcome data. Comparisons in
outcome between different countries should be made in
cohort analyses with comprehensive data on comorbidi-
ties which are not collected with routine outcome surveil-
lance systems. Separate reporting of treatment outcome
in pulmonary and extra-pulmonary tuberculosis should
be considered.
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